Recombinant Mouse CEACAM-1/CD66a protein (rFc Tag)

Species

Mouse

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg1423



Product Information

Purity >90 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Not tested
Expression HEK293-derived Mouse CEACAM-1 protein Glu35-Gly428 (Accession# P31809-1) with a rabbit IgG Fc tag at the C-terminus.
GeneID 26365
Accession P31809-1
PredictedSize 69.9 kDa
SDS-PAGE 80-120 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

CEACAM1, also known as BGP1 or CD66a, belongs to the CEA-related cell-adhesion molecule (CEACAM) subfamily, which is a part of the immunoglobulin superfamily. It plays a role in cell-cell adhesion, regulation of cell proliferation, insulin resistance, obesity, and vascular homeostasis. CEACAM1 is expressed by certain epithelial, endothelial, lymphoid, and myeloid cells. It is found on the surface of various tumors and is associated with tumor progression, metastasis and poor prognosis. CEACAM1 serves as a specific biomarker for Non-small cell lung cancer (NSCLC) and can be used for diagnosis and prognosis of melanoma.

References:

1. Muenzner P. et al. (2007). Cell Microbiol. 10(5):1074-92. 2. Rueckschloss U. et al. (2016). Histochem Cell Biol. 146(6):657-671. 3. Dankner M. et al. ( 2017). Oncoimmunology. 6(7):e1328336. 4. Gray-Owen SD. et al. (2006). Nat Rev Immunol. 6(6):433-46. 5. Gur C, et al. (2019). Oncoimmunology. 8(6):e1581531.